You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMoxifloxacin
Accession NumberDB00218  (APRD00281)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMoxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Structure
Thumb
Synonyms
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
External Identifiers
  • BAY 12-8039
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act MoxifloxacinSolution0.5 %OphthalmicActavis Pharma Company2015-11-04Not applicableCanada
Auro-moxifloxacinTablet400 mgOralAuro Pharma Inc2015-11-04Not applicableCanada
AveloxTablet, film coated400 mg/1OralREMEDYREPACK INC.2013-05-24Not applicableUs
AveloxTablet400 mgOralBayer Inc2000-10-20Not applicableCanada
AveloxTablet, film coated400 mg/1OralPd Rx Pharmaceuticals, Inc.2011-02-25Not applicableUs
AveloxTablet, film coated400 mg/1OralSchering Plough Corporation1999-12-10Not applicableUs
AveloxTablet, film coated400 mg/1OralPhysicians Total Care, Inc.2009-07-16Not applicableUs
AveloxTablet, film coated400 mg/1OralBayer Health Care Pharmaceuticals Inc.1999-12-10Not applicableUs
AveloxInjection, solution400 mg/250mLIntravenousSchering Plough Corporation2001-11-30Not applicableUs
AveloxInjection, solution400 mg/250mLIntravenousBayer Health Care Pharmaceuticals Inc.2001-11-30Not applicableUs
AveloxTablet, coated400 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-07Not applicableUs
AveloxTablet, film coated400 mg/1OralCardinal Health2010-03-02Not applicableUs
AveloxTablet, film coated400 mg/1OralRed Pharm Drug Inc.2011-02-25Not applicableUs
Avelox Abc PackTablet, film coated400 mg/1OralStat Rx USA1999-12-10Not applicableUs
Avelox I.V.Solution400 mgIntravenousBayer Inc2003-06-24Not applicableCanada
Bio-moxifloxacinTablet400 mgOralBiomed Pharma2016-01-15Not applicableCanada
Ipg-moxifloxacinTablet400 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-moxifloxacinTablet400 mgOralJamp Pharma Corporation2015-11-04Not applicableCanada
Jamp-moxifloxacin TabletsTablet400 mgOralJamp Pharma Corporation2016-01-11Not applicableCanada
Mar-moxifloxacinTablet400 mgOralMarcan Pharmaceuticals Inc2015-12-21Not applicableCanada
MoxezaSolution5 mg/mLOphthalmicAlcon Laboratories, Inc.2011-01-18Not applicableUs
MoxifloxacinInjection, solution400 mg/250mLIntravenousFresenius Kabi USA, LLC2015-03-18Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralPd Rx Pharmaceuticals, Inc.2014-01-29Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralPd Rx Pharmaceuticals, Inc.2014-01-29Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralREMEDYREPACK INC.2015-06-29Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralAlvogen, Inc.2014-01-29Not applicableUs
Mylan-moxifloxacinTablet400 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-moxifloxacin HCl Ophthalmic SolutionSolution0.5 %OphthalmicMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PMS-moxifloxacinSolution0.5 %OphthalmicPharmascience Inc2015-12-21Not applicableCanada
PMS-moxifloxacinTablet400 mgOralPharmascience IncNot applicableNot applicableCanada
Priva-moxifloxacinTablet400 mgOralPharmapar Inc2016-01-15Not applicableCanada
Riva-moxifloxacinTablet400 mgOralLaboratoire Riva Inc2016-03-31Not applicableCanada
Riva-moxifloxacinTablet400 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz MoxifloxacinTablet400 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz MoxifloxacinSolution0.5 %OphthalmicSandoz Canada Incorporated2015-10-29Not applicableCanada
Teva-moxifloxacinTablet400 mgOralTeva Canada Limited2015-11-04Not applicableCanada
Teva-moxifloxacinSolution0.5 %OphthalmicTeva Canada LimitedNot applicableNot applicableCanada
VigamoxSolution / drops5 mg/mLOphthalmicA S Medication Solutions2003-05-07Not applicableUs
VigamoxSolution / drops5 mg/mLOphthalmicAlcon Laboratories, Inc.2003-05-07Not applicableUs
VigamoxSolution5 mg/mLOphthalmicREMEDYREPACK INC.2014-10-20Not applicableUs
VigamoxSolution5 mg/mLOphthalmicPhysicians Total Care, Inc.2003-05-22Not applicableUs
VigamoxSolution0.5 %OphthalmicAlcon Canada Inc2004-05-12Not applicableCanada
VigamoxSolution5 mg/mLOphthalmicRebel Distributors Corp2003-05-07Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-moxifloxacinSolution0.5 %OphthalmicApotex Inc2015-11-19Not applicableCanada
Apo-moxifloxacinTablet400 mgOralApotex Inc2016-01-11Not applicableCanada
MoxifloxacinTablet, film coated400 mg/1OralMajor Pharmaceuticals2014-03-05Not applicableUs
MoxifloxacinTablet, film coated400 mg/1OralDr. Reddy's Laboratories Limited2014-03-05Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralTeva Pharmaceuticals USA Inc2014-02-19Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralAv Pak2016-07-22Not applicableUs
Moxifloxacin HydrochlorideTablet400 mg/1OralMylan Pharmaceuticals Inc.2015-08-31Not applicableUs
Moxifloxacin HydrochlorideTablet400 mg/1OralFera Pharmaceuticals, LLC2016-01-222016-11-15Us
Moxifloxacin HydrochlorideTablet400 mg/1OralTorrent Pharmaceuticals Limited2014-04-03Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralCitron Pharma LLC2014-03-04Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralAurobindo Pharma Limited2014-03-04Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralAmerican Health Packaging2014-03-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Moxifloxacin hydrochloride
186826-86-8
Thumb
  • InChI Key: IDIIJJHBXUESQI-DFIJPDEKSA-N
  • Monoisotopic Mass: 437.151762215
  • Average Mass: 437.892
DBSALT000387
Categories
UNIIU188XYD42P
CAS number151096-09-2
WeightAverage: 401.4314
Monoisotopic: 401.175084476
Chemical FormulaC21H24FN3O4
InChI KeyFABPRXSRWADJSP-MEDUHNTESA-N
InChI
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
IUPAC Name
7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O
Pharmacology
IndicationFor the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Structured Indications
PharmacodynamicsMoxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, and Streptococcus viridans group. Aerobic Gram-negative microorganisms: Acinetobacter lwoffii, Haemophilus influenzae, and Haemophilus parainfluenzae. Other microorganisms: Chlamydia trachomatis.
Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
Mechanism of actionThe bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
DNA topoisomerase 2-alphaProteinunknown
inhibitor
HumanP11388 details
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.
Volume of distribution
  • 1.7 to 2.7 L/kg
Protein binding50% bound to serum proteins, independent of drug concentration.
Metabolism

Approximately 52% or oral or intravenous dose is metabolized via glucuronide and sulphate conjugation. The cytochrome P450 system is not involved in metabolism. The sulphate conjugate accounts for 38% of the dose, and the glucuronide conjugate accounts for 14% of the dose.

Route of eliminationApproximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces).
Half life11.5-15.6 hours (single dose, oral)
Clearance
  • 12 +/- 2 L/hr
ToxicitySymptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Moxifloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Moxifloxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Moxifloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Moxifloxacin.Experimental, Illicit
AcarboseMoxifloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Moxifloxacin.Approved
AcenocoumarolMoxifloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Moxifloxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Moxifloxacin.Approved
AlbiglutideMoxifloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Moxifloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Moxifloxacin.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
AlogliptinMoxifloxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Moxifloxacin.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Moxifloxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Moxifloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Moxifloxacin.Approved
AmiodaroneMoxifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Moxifloxacin.Approved
AnagrelideMoxifloxacin may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Moxifloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Moxifloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Moxifloxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Moxifloxacin.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Arsenic trioxideMoxifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMoxifloxacin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineMoxifloxacin may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Moxifloxacin.Approved
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Moxifloxacin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Moxifloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Moxifloxacin.Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Moxifloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Moxifloxacin.Approved, Investigational
BedaquilineMoxifloxacin may increase the QTc-prolonging activities of Bedaquiline.Approved
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Moxifloxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Moxifloxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Moxifloxacin.Approved
BromocriptineMoxifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Moxifloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Moxifloxacin.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Moxifloxacin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Moxifloxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinMoxifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the neuroexcitatory activities of Moxifloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
CeritinibMoxifloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineMoxifloxacin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineMoxifloxacin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideMoxifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Moxifloxacin.Approved, Investigational
CiprofloxacinMoxifloxacin may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMoxifloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramMoxifloxacin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinMoxifloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Moxifloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Moxifloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Moxifloxacin.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
ClonixinClonixin may increase the neuroexcitatory activities of Moxifloxacin.Approved
ClozapineMoxifloxacin may increase the QTc-prolonging activities of Clozapine.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Moxifloxacin.Approved
CrizotinibMoxifloxacin may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Moxifloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Moxifloxacin.Approved, Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Moxifloxacin.Investigational
DabrafenibDabrafenib may increase the QTc-prolonging activities of Moxifloxacin.Approved
DapagliflozinMoxifloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Moxifloxacin.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Moxifloxacin.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Moxifloxacin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Moxifloxacin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Moxifloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Moxifloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Moxifloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Moxifloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Moxifloxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
DicoumarolMoxifloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Moxifloxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Moxifloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Moxifloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Moxifloxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Moxifloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Moxifloxacin.Approved
DisopyramideMoxifloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Moxifloxacin.Approved, Investigational
DofetilideMoxifloxacin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMoxifloxacin may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneMoxifloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Moxifloxacin.Approved
DronedaroneMoxifloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolMoxifloxacin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved
DulaglutideMoxifloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Moxifloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Moxifloxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Moxifloxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Moxifloxacin.Investigational
EliglustatMoxifloxacin may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinMoxifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Moxifloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Moxifloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Moxifloxacin.Approved
EribulinEribulin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
EscitalopramMoxifloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Moxifloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Moxifloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Ethyl biscoumacetateMoxifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Moxifloxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Moxifloxacin.Approved
ExenatideMoxifloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Moxifloxacin.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Moxifloxacin.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Moxifloxacin.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Moxifloxacin.Approved
FenbufenFenbufen may increase the neuroexcitatory activities of Moxifloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved
Ferric CarboxymaltoseThe serum concentration of Moxifloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Moxifloxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Moxifloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
FlecainideMoxifloxacin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineFloctafenine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Moxifloxacin.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Moxifloxacin.Approved
FluindioneMoxifloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Moxifloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Moxifloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Moxifloxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Moxifloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Moxifloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Moxifloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Moxifloxacin.Approved
FluoxetineMoxifloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolMoxifloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Moxifloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Moxifloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Moxifloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Moxifloxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Moxifloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Moxifloxacin.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Moxifloxacin.Approved
Gadobenic acidMoxifloxacin may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Moxifloxacin.Approved
GemifloxacinMoxifloxacin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GliclazideMoxifloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMoxifloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMoxifloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideMoxifloxacin may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Moxifloxacin.Approved
GranisetronMoxifloxacin may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HaloperidolMoxifloxacin may increase the QTc-prolonging activities of Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Moxifloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Moxifloxacin.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Moxifloxacin.Approved
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Moxifloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Moxifloxacin.Approved, Vet Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Moxifloxacin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
IbutilideMoxifloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may increase the neuroexcitatory activities of Moxifloxacin.Approved
IloperidoneMoxifloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Moxifloxacin.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Moxifloxacin.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
Insulin AspartMoxifloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMoxifloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMoxifloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMoxifloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMoxifloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMoxifloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Moxifloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Moxifloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Moxifloxacin can be decreased when it is combined with Iron saccharate.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Moxifloxacin.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Moxifloxacin.Investigational
ItraconazoleItraconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Moxifloxacin.Approved
KebuzoneKebuzone may increase the neuroexcitatory activities of Moxifloxacin.Experimental
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Moxifloxacin.Approved
LanreotideMoxifloxacin may increase the hypoglycemic activities of Lanreotide.Approved
Lanthanum carbonateThe serum concentration of Moxifloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
LeflunomideLeflunomide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
LenvatinibMoxifloxacin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
LevofloxacinMoxifloxacin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LiraglutideMoxifloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Moxifloxacin.Investigational
LithiumLithium may increase the QTc-prolonging activities of Moxifloxacin.Approved
LopinavirMoxifloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamLornoxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved
LumefantrineMoxifloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Moxifloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Moxifloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Moxifloxacin.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Moxifloxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Moxifloxacin.Investigational
MecaserminMoxifloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Moxifloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Moxifloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Moxifloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
MequitazineMoxifloxacin may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
MetforminMoxifloxacin may increase the hypoglycemic activities of Metformin.Approved
MethadoneMoxifloxacin may increase the QTc-prolonging activities of Methadone.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Moxifloxacin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Moxifloxacin.Approved, Vet Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Moxifloxacin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MiglitolMoxifloxacin may increase the hypoglycemic activities of Miglitol.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Moxifloxacin.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Moxifloxacin.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Moxifloxacin.Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Moxifloxacin.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Moxifloxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Moxifloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Moxifloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Moxifloxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Moxifloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
NateglinideMoxifloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Moxifloxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Moxifloxacin.Investigational
NelfinavirNelfinavir may increase the QTc-prolonging activities of Moxifloxacin.Approved
NepafenacNepafenac may increase the neuroexcitatory activities of Moxifloxacin.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Moxifloxacin.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Moxifloxacin.Approved
NilotinibMoxifloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Moxifloxacin.Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Moxifloxacin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
OfloxacinMoxifloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Moxifloxacin.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Moxifloxacin.Approved
OlopatadineOlopatadine may increase the neuroexcitatory activities of Moxifloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved
OndansetronMoxifloxacin may increase the QTc-prolonging activities of Ondansetron.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Moxifloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Moxifloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Moxifloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Moxifloxacin.Approved, Vet Approved
PaliperidoneMoxifloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatMoxifloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Moxifloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Moxifloxacin.Approved
PazopanibMoxifloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineMoxifloxacin may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenMoxifloxacin may increase the QTc-prolonging activities of Perflutren.Approved
PhenindioneMoxifloxacin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonMoxifloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Moxifloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
PimozideMoxifloxacin may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneMoxifloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Moxifloxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
PosaconazolePosaconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational, Vet Approved
PramlintideMoxifloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Moxifloxacin.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Moxifloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Moxifloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Moxifloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Moxifloxacin.Experimental
PrimaquineMoxifloxacin may increase the QTc-prolonging activities of Primaquine.Approved
ProbenecidThe serum concentration of Moxifloxacin can be increased when it is combined with Probenecid.Approved
ProcainamideMoxifloxacin may increase the QTc-prolonging activities of Procainamide.Approved
PromazineMoxifloxacin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Moxifloxacin.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Moxifloxacin.Approved
PropafenoneMoxifloxacin may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Moxifloxacin.Investigational
QuetiapineMoxifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Moxifloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineMoxifloxacin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMoxifloxacin may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
RepaglinideMoxifloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Moxifloxacin.Experimental, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Moxifloxacin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Moxifloxacin.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
RofecoxibRofecoxib may increase the neuroexcitatory activities of Moxifloxacin.Investigational, Withdrawn
RosiglitazoneMoxifloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Moxifloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Moxifloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Moxifloxacin.Approved
SaquinavirMoxifloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinMoxifloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Moxifloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
SitagliptinMoxifloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Moxifloxacin.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
SotalolMoxifloxacin may increase the QTc-prolonging activities of Sotalol.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Moxifloxacin.Investigational
Strontium ranelateThe serum concentration of Moxifloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Moxifloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineMoxifloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Moxifloxacin.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved
SulfisoxazoleMoxifloxacin may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Moxifloxacin.Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Withdrawn
TamoxifenTamoxifen may increase the QTc-prolonging activities of Moxifloxacin.Approved
TelavancinMoxifloxacin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMoxifloxacin may increase the QTc-prolonging activities of Telithromycin.Approved
TenoxicamTenoxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Moxifloxacin.Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Moxifloxacin.Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Moxifloxacin.Approved
TetrabenazineMoxifloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Moxifloxacin.Approved
ThioridazineMoxifloxacin may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Moxifloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Moxifloxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Moxifloxacin.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Moxifloxacin.Approved
TolazamideMoxifloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideMoxifloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Moxifloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Moxifloxacin.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
ToremifeneMoxifloxacin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranilastTranilast may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Moxifloxacin.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Moxifloxacin.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Moxifloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Moxifloxacin.Investigational, Withdrawn
VandetanibMoxifloxacin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Moxifloxacin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Moxifloxacin.Approved, Investigational
VemurafenibMoxifloxacin may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Moxifloxacin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Moxifloxacin.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
WarfarinMoxifloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational, Withdrawn
ZiprasidoneMoxifloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Moxifloxacin.Withdrawn
ZuclopenthixolMoxifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Drink liberally. Absorption is not affected by lipid-rich meals or yogourt.
References
Synthesis Reference

Manne Reddy, Sajja Eswaraiah, Vetukuri Venkata Naga Raju, Rapolu Kumar, Ningam Srinivasreddy, Vedantham Ravindra, “Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof.” U.S. Patent US20050137227, issued June 23, 2005.

US20050137227
General References
  1. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub 2003 Nov 4. [PubMed:14614666 ]
External Links
ATC CodesJ01MA14S01AE07
AHFS Codes
  • 08:12.18
  • 52:04.04
PDB EntriesNot Available
FDA labelDownload (162 KB)
MSDSDownload (193 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9794
Blood Brain Barrier-0.9597
Caco-2 permeable-0.6093
P-glycoprotein substrateSubstrate0.8607
P-glycoprotein inhibitor INon-inhibitor0.7564
P-glycoprotein inhibitor IINon-inhibitor0.7181
Renal organic cation transporterNon-inhibitor0.7318
CYP450 2C9 substrateNon-substrate0.8018
CYP450 2D6 substrateNon-substrate0.8247
CYP450 3A4 substrateNon-substrate0.5756
CYP450 1A2 substrateNon-inhibitor0.7417
CYP450 2C9 inhibitorNon-inhibitor0.7735
CYP450 2D6 inhibitorNon-inhibitor0.8359
CYP450 2C19 inhibitorNon-inhibitor0.7401
CYP450 3A4 inhibitorNon-inhibitor0.8811
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5536
Ames testAMES toxic0.6227
CarcinogenicityNon-carcinogens0.9038
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8092
hERG inhibition (predictor II)Non-inhibitor0.6461
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bayer healthcare pharmaceuticals inc
  • Alcon inc
  • Bayer Healthcare Pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous400 mg/250mL
TabletOral400 mg
Tablet, coatedOral400 mg/1
SolutionIntravenous400 mg
SolutionOphthalmic5 mg/mL
Tablet, film coatedOral400 mg/1
TabletOral400 mg/1
SolutionOphthalmic0.5 %
Solution / dropsOphthalmic5 mg/mL
Prices
Unit descriptionCostUnit
Vigamox 0.5% Solution 3ml Bottle90.72USD bottle
Vigamox 0.5% eye drops27.22USD ml
Avelox 400 mg tablet16.68USD tablet
Avelox abc pack 400 mg tablet16.35USD tablet
Avelox iv 400 mg/250 ml0.17USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1340114 No1998-11-032015-11-03Canada
CA2342211 No2009-05-262019-09-29Canada
US4990517 No1994-12-082011-12-08Us
US5849752 No1996-12-052016-12-05Us
US6548079 No2000-07-252020-07-25Us
US6610327 No1999-10-292019-10-29Us
US6716830 Yes2000-03-292020-03-29Us
US7671070 Yes2000-03-292020-03-29Us
US8450311 No2009-05-292029-05-29Us
US9114168 No2009-05-292029-05-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point238-242 °CNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.168 mg/mLALOGPS
logP0.01ALOGPS
logP-0.5ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)5.69ChemAxon
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.11 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.22 m3·mol-1ChemAxon
Polarizability41.24 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinoline carboxylic acids
Direct ParentQuinoline carboxylic acids
Alternative Parents
Substituents
  • Quinoline-3-carboxylic acid
  • Fluoroquinolone
  • Hydroxyquinoline
  • Dihydroquinolone
  • Aminoquinoline
  • Dihydroquinoline
  • Methoxyaniline
  • Pyrrolopyridine
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • Anisole
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Piperidine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Pyrrolidine
  • Cyclic alcohol
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779 ]
  4. Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Kohrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5. [PubMed:10428935 ]
  5. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC: gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002 Nov;46(11):3418-21. [PubMed:12384345 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29. [PubMed:17910998 ]
  4. Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. Epub 2006 Jul 19. [PubMed:16857688 ]
  5. Perez-Vazquez M, Roman F, Aracil B, Canton R, Campos J: Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J Clin Microbiol. 2004 Mar;42(3):1185-91. [PubMed:15004073 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Reuveni D, Halperin D, Shalit I, Priel E, Fabian I: Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. [PubMed:20596674 ]
  3. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD: Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. doi: 10.1038/nsmb.1892. Epub 2010 Aug 29. [PubMed:20802486 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 04:02